667 related articles for article (PubMed ID: 18408492)
1. Food and Drug Administration approval process for ophthalmic drugs in the US.
Lloyd R; Harris J; Wadhwa S; Chambers W
Curr Opin Ophthalmol; 2008 May; 19(3):190-4. PubMed ID: 18408492
[TBL] [Abstract][Full Text] [Related]
2. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
3. New drug, antibiotic, and biological drug product regulations; accelerated approval--FDA. Final rule.
Fed Regist; 1992 Dec; 57(239):58942-60. PubMed ID: 10123232
[TBL] [Abstract][Full Text] [Related]
4. Applications for approval to market a new drug; complete response letter; amendments to unapproved applications. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Jul; 73(133):39588-611. PubMed ID: 18850675
[TBL] [Abstract][Full Text] [Related]
5. Canadian and US drug approval times and safety considerations.
Rawson NS; Kaitin KI
Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
[TBL] [Abstract][Full Text] [Related]
6. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
Harapanhalli RS
Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
[TBL] [Abstract][Full Text] [Related]
7. Accelerated approval of oncology products: the food and drug administration experience.
Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
[TBL] [Abstract][Full Text] [Related]
8. Biomarker qualification pilot process at the US Food and Drug Administration.
Goodsaid F; Frueh F
AAPS J; 2007 Mar; 9(1):E105-8. PubMed ID: 17408233
[TBL] [Abstract][Full Text] [Related]
9. Regulatory review intervals for ophthalmic new drug applications at the US Food and Drug Administration.
Novack GD
Am J Ophthalmol; 1998 Jul; 126(1):122-6. PubMed ID: 9683158
[TBL] [Abstract][Full Text] [Related]
10. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
[TBL] [Abstract][Full Text] [Related]
11. Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial.
Tsimberidou AM; Braiteh F; Stewart DJ; Kurzrock R
J Clin Oncol; 2009 Dec; 27(36):6243-50. PubMed ID: 19826112
[TBL] [Abstract][Full Text] [Related]
12. Requirements for submission of labeling for human prescription drugs and biologics in electronic format. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2003 Dec; 68(238):69009-20. PubMed ID: 14672084
[TBL] [Abstract][Full Text] [Related]
13. Supplemental applications proposing labeling changes for approved drugs, biologics, and medical devices. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Aug; 73(164):49603-10. PubMed ID: 18958946
[TBL] [Abstract][Full Text] [Related]
14. Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis.
Garrison LP; Towse A; Bresnahan BW
Health Aff (Millwood); 2007; 26(3):684-95. PubMed ID: 17485745
[TBL] [Abstract][Full Text] [Related]
15. A drug's life: the pathway to drug approval.
Keng MK; Wenzell CM; Sekeres MA
Clin Adv Hematol Oncol; 2013 Oct; 11(10):646-55. PubMed ID: 24518374
[TBL] [Abstract][Full Text] [Related]
16. The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology.
McKee AE; Farrell AT; Pazdur R; Woodcock J
Oncologist; 2010; 15 Suppl 1():13-8. PubMed ID: 20237212
[TBL] [Abstract][Full Text] [Related]
17. New drugs for human use; clarification of requirements for patent holder notification--FDA. Proposed rule.
Fed Regist; 1998 Mar; 63(44):11174-7. PubMed ID: 10177511
[TBL] [Abstract][Full Text] [Related]
18. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
[TBL] [Abstract][Full Text] [Related]
19. Ophthalmic drug products for over-the-counter human use; proposed amendment of final monograph--FDA. Proposed rule.
Fed Regist; 1998 Feb; 63(35):8888-90. PubMed ID: 10177740
[TBL] [Abstract][Full Text] [Related]
20. Update on regulatory review intervals for ophthalmic new drug applications at the United States Food and Drug Administration.
Novack GD
Am J Ophthalmol; 2000 Nov; 130(5):664-5. PubMed ID: 11078847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
